12 March 2026 (Thursday) - BTLP-TACT

Well I’ve made a few mistakes with the BTLP-TACT recently, so let’s try again…

It presented me with two cases:

 

22286 – a ninety-six year-old chap with bleeding varices needing four units of FFP. He grouped s A Rh(D) Positive with a negative antibody screen.

However FFP is NOT recommended for bleeding varices so I didn’t issue any.

 

 

26881 – a fifty-one year-old chap in ITU needing two units of blood. He also grouped as A Rh(D) Positive with a negative antibody screen.

I issued two units of A Rh(D) Positive blood

 

I got the thumbs-up. Bearing in mind I’ve had the thumbs-down for three of the last four I saw that as something of a result.

 

10 March 2026 (Tuesday) - The RDW

Here’s something I found randomly on my Facebook feed – a rather useful little dissertation on a much-overlooked blood count parameter; the RDW.

 

9 March 2026 (Monday) - NEQAS 2601DM

 

I got the results of 2601DM this morning. I did it a month ago when I was presented with an image of a blood film and this statement:

 

“A 60-year-old man had commenced treatment for a serious haematological disorder. His white cell count was raised, and platelet count reduced. He then became increasingly anaemic with changed blood film features. You are asked for your opinion. The film arrives outside of normal hours”

 

In my notes I wrote “Well, there’s a bit of everything in this film, isn’t there. The red cells show echinocytes, microspherocytes, blister cells, nucleated red cells, Howell Jolly bodies, rec cell fragments.

The white cells are a bit of a disaster – cerebriform/flower type lymphocytes, toxic granulation, vacuoles in monocytes and neutrophils, smear cells, target cells, pyknotic neutrophils, eosinophilia. 

The platelet appeared reduced, but we were told that anyway.

 

I didn’t fiddle about trying to get the observations in order… time was pressing.

As this arrived out of normal hours I would put it for the consultant to review in the morning… they don’t thank us for being bothered about this sort of thing… this sort of thing being a patient of which they are already well aware”.

 

The expert opinion was rather odd… it waxed on as it so often does but seemed to completely overlook the fact that this was in a patient with a known haematological condition.

But I spotted that which needed spotting and made the right decision

8 March 2026 (Sunday) - Crigler-Naijar Syndrome

Crigler-Najjar syndrome? No – I’d never heard of it either. Here’s a little write-up on the subject. As I always say, a day when you learn nothing is a day wasted.

 

8 March 2026 (Sunday) - Neutrophil Clumping

 I have seen this... but it's not common.

7 March 2026 (Saturday) - BTLP-TACT Exercise

I had a go at the BTLP-TACT thingy today. It presented me with one case – a twenty-nine year-old woman in theatre having an above-knee amputation and needing two units of blood.

She grouped as O Rh(D) Positive with antibody screen positive in all three cells. I requested antibody panels.

The IAT panel was positive in cells 1, 2, 3, 5, 6, 7, 9 and 10 corresponding with anti-S and anti-Fy(a) but not excluding anti-K.

The enzyme panel was negative throughout which excluded quite a bit..

 

I selected two units of O Rh(D) Positive S-negative Fy(a)-negative K-negative

 

I got the thumbs-down. Apparently there was a clinically significant antibody masked but not noted. I’d love to know what it was.

This is a major failing of the BTLP-TACT simulator. You can’t learn anything from your mistakes. 

5 March 2026 (Thursday) - NEQAS 2601 BF

I got the results of NEQAS morphology 2601BF today
 
2601 BF1
 
302   Thrombocytopenia (consensus 1^st)
212      Blast cells (consensus 2^nd)
012   Red cell fragments (consensus 3^th)
213   Promyelocytes (consensus 4^th)
022   NRBC (consensus 5^th)
 
I said ?? acute promyelocytic leukaemia. It was.
 
2601 BF2
 
212      Blast cells (consensus 1^st)
224   Basophilia (consensus 2^nd)
022   NRBC (consensus 3^th)
301   Thrombocytosis (consensus 4^th)
213   Promyelocytes (consensus 8^th)
 
I said ?? CML transforming. It was certainly something transforming, but the expert opinion was rather vague as to what.

 

5 March 2026 (Thursday) - NEQAS 2601 PA

I got the results of NEQAS parasitology 2601PA today
 
2601 PA1
 
I said this was P Falciparum with trophozoites and a parasitaemia of 0.5%
I got the species and the parasitaemia right
 
2602 PA2
I said this was Microfilaria (loa loa)
It was.

3 March 2026 (Tuesday) - Fritsma Factor Update

 

The Fritsma Factor newsletter appeared in my in-box this evening. There was quite a bit to take in, but I’m very grateful for this update. It’s effectively my only way of keeping up with current developments in haemostasis.

3 March 2026 (Tuesday) - Extended DAT Panel (wassat?)

Here’s an interesting case study prompted by a conversation in the lab today… Extended DAT panel… what's that all about?

2 March 2026 (Monday) - Transfusion Evidence Library Update

The nice people at the Transfusion Evidence Library sent their update today. Keeping platelets cold eh? I wonder how long it will be before I’m doing that myself?

ARTICLE OF THE MONTH

Intravenous iron for non-anaemic iron deficiency in pregnancy: a multicentre, two-arm, randomised controlled trial.
Wasim, T., et al. (2026). The Lancet. Haematology.
PICO SUMMARY

 

 

TOP ARTICLES

Efficacy of desmopressin for post-kidney biopsy bleeding complications prevention: a systematic review with frequentist and Bayesian meta-analysis.
Chen, J.J., et al. (2026). Nephrology.

Study of centrifugal therapeutic plasma exchange and membrane therapeutic plasma exchange; a comparative study.
Elghoneimy, H.A., et al. (2025). Therapeutic Apheresis and Dialysis. [Record in progress].

Effects of rhEPO-Fc on chronic renal anemia in Chinese patients undergoing maintenance hemodialysis: a multicenter, randomized, open-label, and phase 3 study.
Gan, L., et al. (2025). Renal Failure.

Risk prediction models for blood transfusion in patients undergoing total hip and knee arthroplasty: a systematic review and meta-analysis.
Liu, X., et al. (2026). Annals of Medicine.

Daprodustat vs recombinant human erythropoietin for anemia and cardiovascular safety in dialysis-dependent and non-dialysis-dependent CKD patients - a systematic review and meta-analysis.
Mishra, H.P., et al. (2026). Current Reviews in Clinical and Experimental Pharmacology. [Record in progress].

Effectiveness of closed blood-sampling devices in critically ill adults: a feasibility trial.
Raurell-Torredà, M., et al. (2026). Nursing in Critical Care.

Liberal versus restrictive blood transfusion strategies in neurocritical care: a systematic review and meta-analysis of randomized controlled trials.
Shaukat, A., et al. (2026). Critical Care Research and Practice.

The effect of online education on cardiovascular intensive care nurses' self-efficacy in blood transfusion: a randomized controlled trial conducted in Turkey.
Songül, A. and Bahar, A. (2025). Transfusion and Apheresis Science.

A pilot trial of long-distance shipped, extended- and cold-stored platelets in 100% plasma for cardiothoracic surgical bleeding.
Stolla, M., et al. (2026). Transfusion. [Record in progress].

1 March 2026 (Sunday) - Beware What You Read...

 Well, it’s intracellular yeast…  The original question had people confidently saying green crystals of death, dohle bodies…

The take-home message here is to be *very* careful about what you read on Facebook haematology groups…

27 February 2026 (Friday) - UKAS Update

The nice people at the UK Accreditation Service sent their update today. You can read it by clicking here. And again I clicked there and read it.

I’ve made no secret that I struggle to see how this stuff is relevant to improve what I actually do on a daily basis, and whoever wrote the newsletter didn’t help by starting off with “Learning as an investment in capability delivers long-term benefits for individuals and organisations by strengthening professional judgement and helping individuals respond confidently to new or complex situations”.

What does that actually mean? Why don’t they write these things in understandable everyday English?

A few less management catch-phrases and a little more comprehensibility all round would help everyone.

 

I’m reminded of my days as a manager when if I ever wanted to get my way in a meeting against a majority decided against me, I would say that my way was the only way that didn’t have serious governance issues. And because very few people knew what a “governance issue” was, most people would back down. And if anyone didn’t, I would scare them off with equally incomprehensible talk of “MHRA requirements”.

26 February 2026 (Thursday) - More Change

And so it all gets changed again... 

24 February 2026 (Tuesday) - IBMS Update

The IBMS sent their update today. You can read it by clicking here. I must admit the only bit which was of any relevance to me was the bit about major hemorrhage protocols… and if there is one thing I would say about blood bankers (apart from how much they love meetings!) is that they provide loads of CPD through all sorts of other outlets.